Radiation Oncology
Prof. Dr. Cengiz Gemici
Clinical Oncology
1. Radiation Therapy: Techniques, equipment, and protocols.
2. Medical Oncology: Understanding the integration of chemotherapy with radiation therapy.
3. Surgical Oncology: Coordination with surgical teams for comprehensive cancer treatment.
4. Palliative Care: Managing symptoms and improving the quality of life for terminal patients.
Radiation Physics
1. Radiation Dosimetry: Measurement and calculation of radiation doses.
2. Radiobiology: Biological effects of radiation on cells and tissues.
3. Imaging Techniques: CT, MRI, PET scans, and their integration with radiation therapy.
4. Treatment Planning: Software and methods for creating effective radiation treatment plans.
Cancer Biology
1. **Tumor Biology**: Growth, progression, and metastasis of cancer cells.
2. **Molecular Oncology**: Genetic and molecular changes in cancer.
3. **Immuno-Oncology**: The role of the immune system in cancer treatment.
4. **Biomarkers**: Identifying biomarkers for prognosis and treatment response.
Patient Care and Management
1. **Patient Assessment**: Evaluating and diagnosing cancer patients.
2. **Side Effect Management**: Identifying and managing radiation therapy side effects.
3. **Patient Education**: Communicating treatment plans and expectations to patients.
4. **Follow-Up Care**: Long-term monitoring of cancer patients post-treatment.
Research and Development
1. Clinical Trials: Designing, conducting, and analyzing clinical trials.
2. New Technologies: Advancements in radiation therapy equipment and techniques.
3. Translational Research: Applying laboratory findings to clinical practice.
4. Data Analysis: Using big data and AI to improve treatment outcomes.
Interdisciplinary Collaboration
1. Multidisciplinary Teams: Working with other healthcare professionals in tumor boards and collaborative care settings.
2. Patient Advocacy: Advocating for patient access to care and treatment.
3. Healthcare Policy: Staying informed about changes in healthcare regulations and policies affecting oncology.
Education:
- 1983-1990: Marmara University Faculty of Medicine.
- 1991-1994: Residency in Radiation Oncology at SSK Okmeydanı Hospital.
- 1994-1995: Diploma from Paris Hospitals College of Medicine.
- 1995-1996: Advanced Specialization in Oncology from Paris XI University, Southern Paris Medical School.
- 1996-1997: Specialization in Medical Oncology from Paris XI University, Southern Paris Medical School.
- 1995-1997: Diploma in Clinical Oncology from Paris XI University, Southern Paris Medical School.
Professional Memberships
- ASTRO: American Society for Therapeutic Radiology and Oncology.
- ASCO: American Society of Clinical Oncology.
Academic Appointments:
- 1994-1997: Radiation and Medical Oncology at Paris Tenon Hospital.
- 1997-2000: Radiation Oncology at Kartal Training and Research Hospital.
- 2000-2017: Head of Radiation Oncology Education at Kartal Training and Research Hospital.
- 2017: Appointed as Associate Professor.
- 2019: Appointed as Professor
1- Volumetric decrease of pancreas after abdominal irradiation, it is time to consider pancreas as an organ at risk for radiotherapy planning. Gemici C, Yaprak G, Ozdemir S, Baysal T, Seseogullari OO, Ozyurt H.
Radiat Oncol. 2018
2- Osteoporosis development and vertebral fractures after abdominal irradiation in patients with gastric cancer. Yaprak G, Gemici C, Temizkan S, Ozdemir S, Dogan BC, Seseogullari OO. BMC Cancer. 2018
3- Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience. Ozyurt H, Ozden AS, Ozgen Z, Gemici C, Yaprak G. Curr Oncol. 2017
4- Radiation field size and dose determine oncologic outcome in esophageal cancer. Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. World J Surg Oncol. 2016
5 - Is there any role of intravenous iron for the treatment of anemia in cancer? Gemici C, Yetmen O, Yaprak G, Ozden S, Tepetam H, Ozyurt H, Mayadagli A. BMC Cancer. 2016
6- Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. Ozcelik M, Korkmaz T, Odabas H, Gemici C, Ercelep O, Yuksel S, Mert AG, Surmeli H, Isik D, Aydin D, Seker M, Mayadagli A, Ozdemir P, Aliustaoglu M, Gumus M. Tumour Biol. 2016
7- Whole-brain radiation therapy for brain metastases: detrimental or beneficial? Gemici C, Yaprak G.
Radiat Oncol. 2015
8- SRS With or Without Whole-Brain Radiation Therapy for Those With 1 to 4 Brain Metastases: In Regard to Sahgal et al. Gemici C, Yaprak G. Int J Radiat Oncol Biol Phys. 2015
9- Neuroendocrine/squamous gastric collision tumor: A rare entity. Erkol B, Tilki M, Comunoğlu N, Öven Ustaalıoğlu BB, Aker F, Sürmelioğlu A, Telli F, Gemici C, Kılıçoğlu ZG, Yeşil A. Turk J Gastroenterol. 2014
10- Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. Ozden S, Ozgen Z, Ozyurt H, Gemici C, Yaprak G, Tepetam H, Mayadagli A. World J Gastroenterol. 2015
11- Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer: in regard to Muijs et al. Gemici C. Int J Radiat Oncol Biol Phys. 2014
12- A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Arican A, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. Support Care Cancer. 2014
13- Progression-free survival benefit or health-related quality-of-life advantage: which one to choose?
Gemici C. J Clin Oncol. 2013
14- Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer. Gemici C, Sargin M, Uygur-Bayramicli O, Mayadagli A, Yaprak G, Dabak R, Kocak M. Radiother Oncol. 2013
15- Co-existence of gastrointestinal stromal tumors with other primary neoplasms. Sevinc A, Seker M, Bilici A, Ozdemir NY, Yildiz R, Ustaalioglu BO, Kalender ME, Dane F, Karaca H, Gemici C, Gumus M, Buyukberber S. Hepatogastroenterology. 2011
16- Lhermitte's sign: Review with special emphasis in oncology practice. Gemici C. Crit Rev Oncol Hematol. 2010
17- Tumor lysis syndrome in solid tumors. Gemici C. J Clin Oncol. 2009
18- Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube. Caglayan B, Torun E, Turan D, Fidan A, Gemici C, Sarac G, Salepci B, Kiral N. Ann Surg Oncol. 2008
19- How can we determine the role of radiotherapy in the treatment of localized aggressive non-Hodgkin's lymphoma?
Gemici C, Salepci T. J Clin Oncol. 2007
20- The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Gemici C. Cancer. 2007
21- Tumour lysis syndrome in solid tumours. Gemici C. Clin Oncol (R Coll Radiol). 2006
22- Endoscopic scoring of late gastrointestinal mucosal damage after adjuvant radiochemotherapy. Dabak R, Uygur-Bayramicli O, Gemici C, Yavuzer D, Sargin M, Yildirim M. World J Gastroenterol. 2006
23- Encapsulating peritonitis and familial Mediterranean fever. Dabak R, Uygur-Bayramiçli O, Aydin DK, Dolapçioglu C, Gemici C, Erginel T, Turan C, Karadayi N. World J Gastroenterol. 2005
24- Erythropoietin to treat anaemia in patients with head and neck cancer. Gemici C. Lancet. 2004
25- Is liver disease an octreotide side effect? Uygur-Bayramiçli O, Gemici C. J Clin Gastroenterol. 2003
26- Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients. Belkacémi Y, Pène F, Touboul E, Rio B, Leblond V, Gorin NC, Laugier A, Gemici C, Housset M, Ozsahin M. Strahlenther Onkol. 1998